Advanced search
Publication Cover
HIV Research & Clinical Practice Volume 23, 2022 - Issue 1
Submit an article Journal homepage
1,453
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies

Mounir Ait-Khaled1 (MA-K, Clinical Science; JS, Clinical Development; JvW, Global Medical), ViiV Healthcare, Brentford, UKCorrespondence[email protected]
View further author information
,
Juan Sierra Madero2 Departamento de Infectología, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, MexicoView further author information
,
Vicente Estrada3 Departamento de Medicina, Hospital Clinico San Carlos, Madrid, SpainView further author information
,
Roberto Gulminetti4 Institute of Infectious Diseases, University of Pavia, Pavia, ItalyView further author information
,
Debbie Hagins5 Georgia Department of Public Health, Coastal Health District, Chatham CARE Center, Savannah, GA, USAView further author information
,
Hung-Chin Tsai6 Department of Medicine, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan;7 Department of Medicine, National Yang Ming Chiao Tung University, Tainan City, TaiwanView further author information
,
Choy Man8 (CM, Clinical Science; BW, Medicines Development; AZ, Medical Affairs), ViiV Healthcare, Research Triangle Park, NC, USAView further author information
,
Jörg Sievers1 (MA-K, Clinical Science; JS, Clinical Development; JvW, Global Medical), ViiV Healthcare, Brentford, UKView further author information
,
Richard Grove9 Statistics, GlaxoSmithKline, Brentford, UKView further author information
,
Andrew Zolopa8 (CM, Clinical Science; BW, Medicines Development; AZ, Medical Affairs), ViiV Healthcare, Research Triangle Park, NC, USA;10 Department of Medicine, Infectious Diseases, Stanford University, Palo Alto, CA, USAView further author information
,
Brian Wynne8 (CM, Clinical Science; BW, Medicines Development; AZ, Medical Affairs), ViiV Healthcare, Research Triangle Park, NC, USAView further author information
&
Jean van Wyk1 (MA-K, Clinical Science; JS, Clinical Development; JvW, Global Medical), ViiV Healthcare, Brentford, UKView further author information
 show all
Pages 9-14 | Received 06 Aug 2021, Accepted 06 Dec 2021, Published online: 16 Dec 2021

References

  • Back D. 2-Drug regimens in HIV treatment: pharmacological considerations. Germs. 2017;7(3):113–114. PMID: 28932710.
  • Cahn P, Sierra MJ, Arribas JR, GEMINI Study Team, et al. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019;393(10167):143–155. PMID: 30420123.
  • Cahn P, Sierra MJ, Arribas JR, et al. Durable efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;83(3):310–318. PMID: 31834000.
  • Cahn P, Sierra Madero J, Arribas JR, et al. Durable efficacy of dolutegravir (DTG) plus lamivudine (3TC) in antiretroviral treatment–naive adults with HIV-1 infection—3-year results from the GEMINI studies. Poster Presented at: HIV Drug Therapy; October 5-8, 2020; Glasgow.
  • Altice F, Evuarherhe O, Shina S, Carter G, Beaubrun AC. Adherence to HIV treatment regimens: systematic literature review and meta-analysis. Ppa. 2019;13:475–490. PMID: 31040651.
  • Sax PE, Pozniak A, Montes ML, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet 2017;390(10107):2073–2082. PMID: 28867499.
  • Byrd KK, Hou JG, Hazen R, for the Patient-Centered HIV Care Model Team, et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. J Acquir Immune Defic Syndr. 2019;82(3):245–251. PMID: 31343455.
  • US Food and Drug Administration, Center for Drug Evaluation and Research. Human immunodeficiency virus-1 infection: developing antiretroviral drugs for treatment. Guidance for industry. Department of Health and Human Services. https://www.fda.gov/regulatory-information/search-fda-guidance-documents/human-immunodeficiency-virus-1-infection-developing-antiretroviral-drugs-treatment. Updated November 2015. Accessed March 28, 2021.
  • Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26(4):404–413.
  • Underwood M, Wang R, Benson P, et al. DTG + 3TC vs DTG + TDF/FTC (GEMINI-1 & -2): confirmed virologic withdrawals through Week 96. Poster Presented at: Conference on Retroviruses and Opportunistic Infections, March 8-11, 2020; Boston, MA.
  • Lehmann A, Aslani P, Ahmed R, et al. Assessing medication adherence: options to consider. Int J Clin Pharm. 2014;36(1):55–69. PMID: 24166659.
  • Anghel LA, Farcas AM, Oprean RN. An overview of the common methods used to measure treatment adherence. Med Pharm Rep. 2019;92(2):117–122. PMID: 31086837.
  • Centers for Disease Control and Prevention. Partnership for health - medication adherence. US Department of Health and Human Services. https://www.cdc.gov/hiv/effective-interventions/treat/pfh-ma/index.html?Sort=Priority%3A%3Aasc&Intervention%20Name=Partnership%20for%20Health%20-%20Medication%20Adherence. Updated July 21, 2020. Accessed March 28, 2021.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.